Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

This study is currently recruiting participants.
Verified January 2013 by University Hospital of Liege
Sponsor:
Collaborators:
AZ Sint-Jan AV
Ziekenhuis Netwerk Antwerpen (ZNA)
Jules Bordet Institute
University Hospital, Gasthuisberg
AZ-VUB
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University Hospital, Antwerp
Cliniques Universitaires de Mont-Godinne
Jolimont Hospital Haine Saint Paul
Queen Fabiola Children's University Hospital
University Hospital, Ghent
H.-Hart Hospital Roeselare-Menen
Information provided by (Responsible Party):
Yves Beguin, University Hospital of Liege
ClinicalTrials.gov Identifier:
NCT01428973
First received: September 1, 2011
Last updated: January 17, 2013
Last verified: January 2013

September 1, 2011
January 17, 2013
September 2011
September 2016   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
To compare the 1-year progression-free survival between the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
Same as current
Complete list of historical versions of study NCT01428973 on ClinicalTrials.gov Archive Site
  • Relapse rate; nonrelapse mortality and overall survival [ Time Frame: 1, 2 and 5 years after transplantation ] [ Designated as safety issue: No ]
    To compare relapse rate, nonrelapse mortality, and overall survival in the 2 prophyltic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) 1, 2 and 5 years after hematopietic stem cell transplantation (HSCT) in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Progression free survival [ Time Frame: 2 and 5 years after transplantation ] [ Designated as safety issue: No ]
    To compare progression-free survival in the 2 phrophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) 2 and 5 years after HSCT, in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Engraftment [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
    To compare hematopoietic (whole blood and T cell chimerism) engraftment and to evaluate the 1-year incidence of graft rejection in the 2 prophylctic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Acute GVDH [ Time Frame: 6 months after transplantation ] [ Designated as safety issue: No ]
    To compare the 6-mo incidence of grades II-IV and III-IV acute GVHD in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Chronic GVDH [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
    To compare the 1-yr incidence of chronic GVHD in the phrophylactic 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Immunological reconstitution [ Time Frame: 3 mo, 6 mo, 1 yr, 2 yrs and 5 yrs after transplantation ] [ Designated as safety issue: No ]
    To compare the quality and timing of immunologic reconstitution in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus),in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Infection [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
    To compare the 1-yr incidences of bacterial, fungal and viral infections in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Relapse rate; nonrelapse mortality and overall survival [ Time Frame: 1, 2 and 5 years after transplantation ] [ Designated as safety issue: No ]
    To compare relapse rate, nonrelapse mortality, and overall survival in the 2 prophyltic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) 1, 2 and 5 years after HSCT in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Progression free survival [ Time Frame: 2 and 5 years after transplantation ] [ Designated as safety issue: No ]
    To compare progression-free survival in the 2 phrophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus) 2 and 5 years after HSCT, in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Engraftment [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
    To compare hematopoietic (whole blood and T cell chimerism) engraftment and to evaluate the 1-year incidence of graft rejection in the 2 prophylctic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Acute GVDH [ Time Frame: 6 months after transplantation ] [ Designated as safety issue: No ]
    To compare the 6-mo incidence of grades II-IV and III-IV acute GVHD in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Chronic GVDH [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
    To compare the 1-yr incidence of chronic GVHD in the phrophylactic 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Immunological reconstitution [ Time Frame: 3 mo, 6 mo, 1 yr, 2 yrs and 5 yrs after transplantation ] [ Designated as safety issue: No ]
    To compare the quality and timing of immunologic reconstitution in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus),in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
  • Infection [ Time Frame: 1 year after transplantation ] [ Designated as safety issue: No ]
    To compare the 1-yr incidences of bacterial, fungal and viral infections in the 2 prophylactic arms (Tracolimus/Mycophenolate Mofetil and Tracolimus/Sirolimus), in the whole group of patients and separately in those conditioned with Fluradabine/TBI or Fluradabine plus Busulfan and anti-thymocyte globulin.
Not Provided
Not Provided
 
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donors After Reduced-intensity Conditioning: a Phase II Randomized Study Comparing 2 GVHD Prophylaxis Regimens

The present project is a multicenter phase II trail aiming at comparing which of the two postgrafting immunosuppressive regimens proposed in this study will be best suited to prevent graft-versus-host disease (GVDH).

The immunosuppressive regimens will consist of: Tacrolimus plus Mycophenolate Mofetil or Tacrolimus plus Sirolimus. Before grafting patients will undergo two reduced-intensity conditioning: Fludarabine/total body irradiation (TBI) or Fludarabine+Busulfan+anti-thymocyte globulin. The hypothesis is that the Tacrolimus plus Sirolimus regimen will be associated with better progression-free survival due to a lower incidence of relapse/progression.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
  • Graft-Versus-Host Disease
  • Hematological Malignancies
  • Drug: Mycophenolate mofetil
    Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
    Other Name: CellCept
  • Drug: Sirolimus
    Tablets. 6 mg loading dose on day −3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
    Other Name: Rapamune
  • Active Comparator: Arm 1
    GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
    Intervention: Drug: Mycophenolate mofetil
  • Experimental: Arm 2
    GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day −3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
    Intervention: Drug: Sirolimus
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
September 2017
September 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Hematological malignancies confirmed histologically and not rapidly progressing:

    • Acute myeloid leukemia (AML) in complete remission (CR) (defined as ≤ 5% marrow blasts and absence of blasts in the peripheral blood);
    • Myelodysplastic syndromes (MDS) with ≤ 5% marrow blasts and absence of blasts in the peripheral blood;
    • Chronic myeloid leukemia (CML) in chronic phase (CP);
    • Myeloproliferative neoplasms not in blast crisis and not with extensive marrow fibrosis;
    • Acute lymphoid leukemia (ALL)in CR;
    • Multiple myeloma not rapidly progressing;
    • chronic lymphocytic leukemia (CLL);
    • Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);
    • Hodgkin's disease with chemosensitive disease;
  2. 10/10 HLA-A, -B, -C, DRB1 and DQBI allele-matched donor fit to/willing to donate PBSC.
  3. Clinical situations:

    1. Theoretical indication for a standard allotransplant, but not feasible because:

      • Age > 50 yrs;
      • Unacceptable end organ performance;
      • At the physician's decision;
      • Patient's refusal.
    2. Indication for a standard auto-transplant: perform mini-allotransplantation 2-6 months after standard autotransplant.
  4. Other inclusion criteria:

    • Male or female; fertile patients must use a reliable contraception method;
    • Age ≤ 75 yrs (children of any age are allowed in the protocol);
    • Informed consent given by patient or his/her guardian if of minor age.

Exclusion Criteria:

  • Any condition not fulfilling inclusion criteria;
  • HIV positive;
  • Non-hematological malignancy(ies) (except non-melanoma skin cancer) < 3 years before nonmyeloablative hematopoietic cell transplantation (HCT);
  • Life expectancy severely limited by disease other than malignancy;
  • Administration of cytotoxic agent(s) for "cytoreduction" within three weeks prior to initiating the nonmyeloablative transplant conditioning (Exceptions are hydroxyurea and imatinib mesylate);
  • CNS involvement with disease refractory to intrathecal chemotherapy;
  • Terminal organ failure, except for renal failure (dialysis acceptable)

    1. Cardiac: Symptomatic coronary artery disease or other cardiac failure requiring therapy; ejection fraction <35%; uncontrolled arrhythmia, uncontrolled hypertension;
    2. Pulmonary: DLCO < 35% and/or receiving supplementary continuous oxygen;
    3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin >3 mg/dL, and symptomatic biliary disease;
  • Uncontrolled infection;
  • Karnofsky Performance Score <70%;
  • Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment;
  • Patient is a female who is pregnant or breastfeeding;
  • Any condition precluding the use of sirolimus or MMF;
  • One HLA mismatch with peripheral blood stem cells (PBSC) fit to/willing to donate.
Both
16 Years to 75 Years
No
Contact: Frédéric Baron, MD; PhD 32-4-3667201 F.Baron@ulg.ac.be
Contact: Yves Beguin, MD; PhD 32-4-3667201 yves.beguin@chu.ulg.ac.be
Belgium
 
NCT01428973
TJB1016P1
No
Yves Beguin, University Hospital of Liege
University Hospital of Liege
  • AZ Sint-Jan AV
  • Ziekenhuis Netwerk Antwerpen (ZNA)
  • Jules Bordet Institute
  • University Hospital, Gasthuisberg
  • AZ-VUB
  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain
  • University Hospital, Antwerp
  • Cliniques Universitaires de Mont-Godinne
  • Jolimont Hospital Haine Saint Paul
  • Queen Fabiola Children's University Hospital
  • University Hospital, Ghent
  • H.-Hart Hospital Roeselare-Menen
Principal Investigator: Frédéric Baron, MD; PhD University of Liège
University Hospital of Liege
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP